( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Jazz Pharmaceuticals plc

06 Jun, 2018, 21:05 BST Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Goldman Sachs 39th...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of...


31 May, 2018, 13:30 BST New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea

Survey findings show that while pulmonologists, neurologists and psychiatrists are aware of the negative effects of Excessive Sleepiness (ES) on...


24 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on solriamfetol...


10 May, 2018, 13:30 BST Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting

Twenty abstracts including eight oral presentations to showcase Jazz's breadth and depth of sleep medicine innovation Jazz Pharmaceuticals...


09 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


08 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results

Total Revenues Increased 18% to $445 Million Supplemental New Drug Application Submitted to FDA for Xyrem in the Treatment of Pediatric Narcolepsy...


01 May, 2018, 13:30 BST Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug...


24 Apr, 2018, 21:05 BST Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018, after...


06 Mar, 2018, 21:05 GMT Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


02 Mar, 2018, 13:30 GMT Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard...


27 Feb, 2018, 21:05 GMT Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results

Total Revenues of $1.6 Billion in 2017 GAAP EPS of $7.96 Per Share in 2017 Adjusted Non-GAAP EPS of $11.04 Per Share in 2017 Solriamfetol New...


23 Feb, 2018, 13:30 GMT Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the...


13 Feb, 2018, 21:05 GMT Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday,...


08 Feb, 2018, 21:15 GMT National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN®) added Vyxeos™ (daunorubicin and...


02 Jan, 2018, 21:05 GMT Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P....


21 Dec, 2017, 13:30 GMT Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...


07 Dec, 2017, 21:05 GMT Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets...


04 Dec, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer,...


09 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


07 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Total Revenues Increased 10% to $412 Million Launched Vyxeos in the U.S. in August 2017 Vyxeos EU Marketing Authorization Application Submission...


03 Nov, 2017, 12:30 GMT Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Vyxeos granted accelerated assessment review status from European Medicines Agency's Committee for Medicinal Products for Human Use Jazz...


01 Nov, 2017, 13:29 GMT Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting

Nineteen abstracts accepted for three Jazz hematology/oncology products Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that thirteen...


24 Oct, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017,...